Starting dose final guidance
FDA final guidance on "FDL-1Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers," released July 22, provides an algorithm by which maximum recommended starting dose (MRSD) can be selected for first-in-human clinical trials. Document generally reflects draft version. The process outlined for calculating MRSD uses administered doses, observed toxicities and an algorithmic approach, although "an alternative approach could be proposed that places primary emphasis on animal pharmacokinetics and modeling rather than dose," FDA says. Merck and Bristol-Myers Squibb had requested that the process include alternate methods for deriving MRSD rather than a single approach (1"The Pink Sheet" May 12, 2003, p. 23)...
You may also be interested in...
FDA should expand on alternative methods for selecting a starting dose in clinical trials in addition to the algorithm recommended in a draft guidance, Merck and Bristol-Myers Squibb say in comments
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Judge ordering permanent injunction against Confidence USA on a complaint filed in 2019 questioned FDA's calculations for requiring the firm to recall and destroy all products it had distributed since February 2018.